Try it on your cases ↗︎Contact us ↗︎
MENU

FOR CLINICIANS AND TUMOR BOARDS

For cliniciansand tumor boards.

Explore the evidence relevant to biomarker results, recurrence risk and treatment benefit.

DIAKWANT®: CE MARKED UNDER IVDR, CLASS C, IN THE EUDiaSurv® and DiaThera®: Research Use Only

* CE marking applies to DiaKwant® only. Other assays shown here are Research Use Only.

YOUR CLINICAL QUESTIONS

Find the answers that matter to your clinical question.

Review the biomarker score, explore recurrence risk and understand the question of treatment benefit through our three AI assays.

BIOMARKER RESULTS

DiaKwant®

Discuss treatment options using biomarker scores your pathologist has reviewed against the quantified findings. You receive the score in the pathology report, and the regions and counts remain in your pathologist's viewer.

↗︎RECURRENCE RISK*

DiaSurv®*

Which patients face a higher risk of recurrence? DiaSurv®* focuses on recurrence risk, with the goal of helping tailor treatment intensity and follow-up to the patient.

↗︎TREATMENT RESPONSE*

DiaThera®*

Who stands to benefit from this treatment? DiaThera®* focuses on treatment response, with the goal of helping match patients to therapies likely to benefit them.

↗︎

TREATMENT INTENSITY

Help match treatment intensity to each patient's needs.

Recurrence risk and expected treatment benefit are central to avoiding overtreatment and undertreatment. These questions drive the development of DiaSurv®* and DiaThera®*.

RECURRENCE RISK & TREATMENT RESPONSE

Discuss recurrence risk and treatment response for your patients.

Connect your clinical question with a DiaSurv® or DiaThera® research project, and review DiaKwant® biomarker scores with your pathology laboratory.

Contact us ↗︎